Evidence map›Paper›PMID 26855158›Full record

ArticleBone marrow transplantation2016

Risk factors and outcome of graft failure after HLA matched and mismatched unrelated donor hematopoietic stem cell transplantation: a study on behalf of SFGM-TC and SFHI.

T Cluzeau, J Lambert, N Raus, K Dessaux, L Absi, F Delbos, A Devys, M De Matteis, V Dubois, M Filloux and 17 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

T CluzeauService d'hématologie adulte, Hôpital Saint-Louis, APHP, Paris, France.
J LambertHôpital Saint-Louis, Service de Biostatistique et Information Médicale, APHP, Paris, France.
N RausData Management of SFGM-TC, Centre Hospitalier Lyon Sud, Pierre-Bénite, France.
K DessauxHôpital Saint-Louis, Service de Biostatistique et Information Médicale, APHP, Paris, France.
L AbsiLaboratory of Histocompatibility, EFS Saint Etienne, Saint Etienne, France.
F DelbosLaboratory of Histocompatibility, EFS Henri Mondor, Créteil, France.
A DevysLaboratory of Histocompatibility, EFS Pays de la Loire, Nantes, France.
M De MatteisLaboratory of Immunology, CHU Nice, Nice, France.
V DuboisLaboratory of Histocompatibility, EFS Rhone Alpes, Lyon, France.
M FillouxLaboratory of Immunology, CHU Limoges, France.
M FortLaboratory of Immunology, CHU Toulouse, Toulouse, France.
F HauLaboratory of Histocompatibility, EFS Normandie, Rouen, France.
I JolletLaboratory of Histocompatibility, EFS CA, Poitiers, France.
M LabaletteLaboratory of Immunology, CHU Lille, Lille, France.
D MassonLaboratory of Histocompatibility, EFS Rhône Alpes, Grenoble, France.
B MercierLaboratory of Histocompatibility, CHU Brest, France.
B PedronLaboratory of Immunology, Hôpital Robert Debré, APHP, Paris, France.
P PerrierLaboratory of Histocompatibility, CHU Nancy, Nancy, France.
C PicardLaboratory of Histocompatibility, EFS Alpes Mediterrannée, Marseille, France.
F QuainonLaboratory of Histocompatibility, EFS Clermont-Ferrand, Clermont-Ferrand, France.
A Ramounau-PigotLaboratory of Immunology, Hôpital Saint-Eloi, Montpellier, France.
V RenacLaboratory of Histocompatibility, EFS Rennes, France.
P Van EndertLaboratory of Immunology, CHU Necker-Enfants Malades, Paris, France.
D CharronLaboratory of Immunology and Histocompatibility, Hôpital Saint-Louis, APHP, Labex Transplantex, Paris, France.
R Peffault de la TourService d'hématologie greffe, Hôpital Saint-Louis, APHP, Paris, France.
J L TaupinLaboratory of Immunology and Immunogenetics, CNRS UMR 5164, CHU Bordeaux, France.
P LoiseauLaboratory of Immunology and Histocompatibility, Hôpital Saint-Louis, APHP, Labex Transplantex, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Graft failure remains a severe complication of hematopoietic stem cell transplantation (HSCT). Several risk factors have already been published. In this study, we re-evaluated them in a large cohort who had the benefit of the recent experience in HSCT (2006-2012). Data from 4684 unrelated donor HSCT from 2006 to 2012 were retrospectively collected from centers belonging to the French Society for Stem Cell Transplantation. Among the 2716 patients for whom HLA typing was available, 103 did not engraft leading to a low rate of no engraftment at 3.8%. In univariate analysis, only type of disease and status of disease at transplant for malignant diseases remained significant risk factors (P=0.04 and P<0.0001, respectively). In multivariate analysis, only status of disease was a significant risk factor (P<0.0001). Among the 61 patients who did not engraft and who were mismatched for 1 HLA class I and/or HLA-DP, 5 donor-specific antibodies (DSAs) were detected but only 1 was clearly involved in graft failure, for the others their role was more questionable. Second HSCT exhibited a protective although not statistically significant effect on OS (hazard ratio=0.57 [0.32-1.02]). In conclusion, only one parameter (disease status before graft) remains risk factor for graft failure in this recent cohort.

Indexed as

HistocompatibilityUnrelated DonorsAdultGraft RejectionHematopoietic Stem Cell TransplantationHumansMiddle AgedNeoplasmsRetrospective StudiesRisk FactorsSurvival RateTransplantation ImmunologyTreatment Outcome

Identifiers

PMID26855158

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.